Improvement in well-being and remission seen with aripiprazole-augmentation of existing antidepressants
In 11 comparisons, antidepressants were efficacious, but they were inefficacious or evidence was inconclusive for 31 comparisons
Only crude associations seen between risk for neurodevelopmental outcomes and exposure to antidepressants
Hypothesis that depression is caused by low serotonin not supported; some evidence shows decrease in serotonin with antidepressant use
Maternal use of SSRIs, SNRIs in first trimester of pregnancy not linked to increased risk for neonatal seizures or childhood epilepsy in offspring
No improvement seen in physical or mental health-related quality of life
Combinations using an antagonist of presynaptic α2-autoreceptors may be an option for depression that does not respond to monotherapy
Greatest decline in incident stimulant and anxiolytic/sedative-hypnotic medications was in quarter 2 of 2020
Relative risks for mortality significantly reduced for any SSRI, fluoxetine, and fluoxetine or fluvoxamine
In randomized, double-blind trial, no difference seen in scores for agitated behaviors at 12 weeks with mirtazapine versus placebo